Hims & Hers Health, Inc. (NYSE: HIMS) has recently become one of the most polarizing tickers on Wall Street. Following its Q1 2026 earnings report in May 2026, hims stock suffered a sharp 23% sell-off, leaving investors wondering if the company's hyper-growth trajectory has hit a permanent roadblock. The market panicked over an unexpected quarterly net loss of $92.1 million and compressed gross margins. However, beneath these messy headline numbers lies a deliberate, multi-billion-dollar transformation. This deep-dive analysis unpacks HIMS stock, evaluating the company’s pivotal shift to branded GLP-1 medications, its $1.15 billion acquisition of Eucalyptus Health, and whether this dip is a generational buying opportunity or a value trap.

The Q1 2026 Earnings Post-Mortem: Why the Market Panicked

To understand the current state of hims stock, one must first unpack the complex financial results released on May 11, 2026. For a stock that had been priced for perfection—driven by explosive growth in its weight loss segment—the first-quarter earnings report felt like a cold shower for retail and institutional investors alike.

The Double Miss: Expectations vs. Reality

Going into the print, Wall Street anticipated continued GAAP profitability and steady revenue growth. Instead, Hims & Hers delivered a highly unexpected "double miss":

• Earnings Per Share (EPS): The company reported an unexpected net loss of $92.1 million, translating to an EPS of -$0.44 (or -$0.40 depending on the specific adjustments), compared to the analyst consensus estimate of a +$0.04 profit. This represented an EPS miss of more than 1,000% on the bottom line.
• Revenue: Quarterly revenue clocked in at $608 million. While this represented a 4% year-over-year increase compared to Q1 2025, it fell short of the consensus expectation of $616.5 million. Compared to the blistering 59% year-over-year revenue growth reported for the full year 2025 ($2.35 billion), a 4% growth rate in Q1 suggested a severe, sudden deceleration.

The Culprit: Margin Contraction and Write-Downs

The most alarming metric for technical traders was the sharp contraction in gross margins. Historically, Hims & Hers boasted software-like gross margins hovering around 73% to 75%. In Q1 2026, however, margins compressed heavily to 65%.

This contraction was driven by two major factors: first, the company incurred approximately $33 million in restructuring costs and transition expenses. Second, it had to write down a significant amount of existing compounding inventory and capital assets. As Hims & Hers rapidly dismantled its high-margin compounded GLP-1 programs to make way for branded drugs, it absorbed substantial short-term operational friction.

The Silver Lining: A Massive Guidance Upgrade

If the Q1 numbers were truly disastrous, hims stock would have collapsed permanently. Yet, management threw a powerful counterpunch. In the very same report, CEO Andrew Dudum and his team raised their full-year 2026 revenue guidance to a range of $2.8 billion to $3.0 billion (up from the previous guide of $2.7 billion to $2.9 billion). Furthermore, they updated their full-year Adjusted EBITDA guidance to a strong range of $275 million to $350 million.

This upgrade reveals a fundamental truth: the operational headwinds experienced in Q1 were not a sign of a broken business model, but rather the "clearing of the decks" for a massive strategic pivot. The underlying demand remains exceptionally strong, with the company anticipating a dramatic growth acceleration in the second half of 2026.

The Branded GLP-1 Pivot: Turning Novo Nordisk from Foe to Friend

The central driver of the volatility in hims stock over the past year has been its weight loss segment. In late 2025, Hims & Hers experienced a parabolic rise in subscriber count by offering affordable compounded GLP-1 medications (such as compounded semaglutide). These customized compounds allowed Hims to bypass traditional supply shortages and offer massive discounts to customers who could not afford or access branded drugs like Wegovy or Ozempic.

The Legal and Regulatory Showdown

However, this compounding strategy was always a regulatory tightrope. In early February 2026, Hims & Hers attempted to take its strategy a step further by launching a cheaper, off-brand version of Novo Nordisk's oral Wegovy pill, priced at an introductory rate of $49 to $99 per month.

This move triggered immediate retaliation. Novo Nordisk publicly vowed to sue Hims & Hers, labeling the product as an "unapproved, inauthentic, and untested knockoff". Concurrently, the FDA ramped up enforcement and scrutiny on compounded GLP-1 copies, warning platforms that the legal loopholes allowing compounding would rapidly tighten once branded shortages were resolved. For investors in hims stock, the threat of an existential lawsuit from a Danish pharmaceutical giant and federal regulatory crackdowns became a massive cloud hanging over the business.

The Historic March 9, 2026 Agreement

Recognizing the immense risk, Andrew Dudum executed what is now being seen as a masterstroke of corporate diplomacy. On March 9, 2026, Hims & Hers and Novo Nordisk officially announced a groundbreaking strategic partnership, laying down their legal swords.

Under the terms of the agreement:

1. Direct Branded Integration: Hims & Hers became an official distributor of Novo Nordisk's authentic, FDA-approved GLP-1 medications. Eligible customers can now access Wegovy injectables (ranging from 0.25 mg to 2.4 mg) and the highly anticipated Wegovy oral pills (doses up to 25 mg) directly through the Hims & Hers telehealth platforms.
2. Affordable Cash Pay Pricing: Starting as low as $149 per month cash-pay (excluding medication costs), Hims & Hers makes access to these branded blockbuster treatments simpler and more transparent than ever before.
3. Compounding Phase-Out: Hims & Hers agreed to immediately stop advertising compounded GLP-1s and is actively transitioning its existing compounded weight loss subscribers onto the approved, branded Novo Nordisk products. In exchange, Novo Nordisk dismissed its patent infringement lawsuit.

The Long-Term Strategic Value

While this pivot crushed short-term gross margins—since reselling branded drugs from Novo Nordisk is less profitable than formulating compounded semaglutide in-house—it represents an enormous long-term moat. Hims & Hers has transformed from an "adversary" of big pharma into their largest digital front door.

By leveraging its consumer-centric app and marketing engine, Hims & Hers is onboarding roughly 100,000 new weight loss subscribers per month. With Wegovy shipments exceeding 125,000 within just the first six weeks of the partnership, the volume-based economics of this deal are set to drive massive scale, eventually expanding operating margins as supply-chain efficiencies kick in.

Going Global: The $1.15 Billion Eucalyptus Acquisition

While the market focused entirely on the GLP-1 drama in the United States, Hims & Hers quietly laid the groundwork for its next major growth chapter: international dominance. On February 19, 2026, the company announced a definitive agreement to acquire Eucalyptus Health, an international digital healthcare leader, in a transaction valued at up to $1.15 billion.

Who is Eucalyptus Health?

Based in Australia, Eucalyptus is widely regarded as the "Hims & Hers of the Eastern Hemisphere." The company operates a highly successful, vertically integrated portfolio of direct-to-consumer digital clinics, including:

• Juniper: A leading clinical weight loss platform active in Australia, the UK, Germany, and Japan.
• Pilot: A men's preventative health brand focusing on sexual health and hair loss.
• Compound: A high-end, personalized clinical care service.

Eucalyptus brings approximately 775,000 active subscribers and an annualized revenue run rate exceeding $450 million. More importantly, Eucalyptus has achieved triple-digit year-over-year annualized revenue growth throughout 2025, demonstrating that the global appetite for digital-first healthcare is expanding rapidly.

The Strategic Rationale

The acquisition, set to officially close in mid-2026, immediately solves several growth bottlenecks for Hims & Hers:

• Instant Geographic Diversification: Rather than building international infrastructure from scratch, Hims & Hers gains a dominant, regulated footprint across Australia, Japan, Canada, Germany, and the UK.
• Infrastructure and Local Expertise: Eucalyptus brings local clinical networks, localized supply chains, and established relationships with international medical regulators. This drastically reduces the time-to-market for Hims & Hers' core product suite abroad.
• Cross-Pollination of Brands: Over time, Eucalyptus's brands will transition under the Hims & Hers umbrella, creating a global powerhouse that can negotiate directly with multinational pharmaceutical firms on a global scale.

Financing the Global Playbook

To preserve its pristine balance sheet and maintain capital allocation flexibility, Hims & Hers priced an upsized $350 million convertible senior notes offering in mid-May 2026. The notes feature a highly favorable capped call transaction structure with an initial cap price of $50.15 per share—representing a 125% premium over the trading price at the time of issuance.

By securing this low-interest non-dilutive capital, Hims & Hers is fully funded to close the Eucalyptus transaction, scale its global AI-driven diagnostic platform, and execute on international supply-chain efficiencies without diluting existing equity holders at depressed stock prices.

Valuation, Technical Analysis, and the Short Squeeze Dynamic

With hims stock trading in the $23 to $25 range in late May 2026, the valuation of the company has become highly compelling for value-oriented growth investors. The stock is down over 52% over the past year, representing a massive divergence from the underlying operational performance.

A Highly Undervalued Growth Machine

Consider the fundamental valuation metrics:

• Revenue Multiple: With a market capitalization of approximately $5.2 billion and guided 2026 revenue of $2.8 billion to $3.0 billion, HIMS stock trades at a forward Enterprise Value-to-Sales (EV/S) multiple of just 1.7x.
• Price-to-Gross Profit: Based on a normalized post-transition gross margin of 65% to 67%, the company is on track to generate roughly $1.9 billion in gross profit in 2026. This places Hims & Hers at a Price/Gross Profit multiple of under 4x—a valuation usually reserved for low-growth retail businesses, not hyper-growth digital disruptors.
• GF Value Verdict: According to GuruFocus's proprietary intrinsic value calculations, the fair value of HIMS stock is currently estimated at $37.38, implying a significant 32.6% margin of safety from its current trading levels.

Technical Support Levels

From a technical perspective, the post-earnings sell-off pushed HIMS stock into heavily oversold territory. The daily Relative Strength Index (RSI) dipped below 30, signaling an extreme near-term selling climax.

Crucially, the stock has found firm support near its 200-day Simple Moving Average (SMA). Historically, this moving average has served as a primary accumulation zone for institutional buyers. Volume has also begun to dry up on down days, suggesting that the weak-handed retail panic has concluded, and long-term accumulation has commenced.

The 30% Short Interest: Fuel for a Squeeze

One of the most exciting aspects of hims stock is its massive short interest. Currently, roughly 30% to 35% of the total float is held short by hedge funds and traders betting on the demise of the company's compounding business.

Because the short sellers' primary thesis—that Hims & Hers would be sued out of existence by Novo Nordisk—was completely invalidated by the March 9 partnership, these short positions are now highly vulnerable. As Hims & Hers begins to show margin stabilization and subscriber growth acceleration in its Q2 and Q3 2026 reports, any positive earnings surprise will force short sellers to cover. This heavy short cover, combined with natural institutional buying, could trigger a violent upward short squeeze.

The Bull vs. Bear Case: Weighing the Risks and Rewards

As with any high-beta growth stock, investing in Hims & Hers requires an objective look at both the upside potential and the structural risks. Here is how the investment thesis shakes out for long-term holders:

The Bull Case

• The Branded Moat: The partnership with Novo Nordisk legitimizes Hims & Hers as a mainstream, trusted medical platform. It eliminates legal and regulatory risks, paving the way for similar collaborations with other big pharma giants (such as Eli Lilly).
• Global Scale: The Eucalyptus acquisition instantly positions Hims & Hers as a leading global consumer health platform, providing a highly diversified, multi-continental revenue stream.
• Operating Leverage: Once the one-time integration and restructuring costs of 2026 are fully absorbed, the company's high customer retention rates and automated AI-diagnostic tools will drive rapid Adjusted EBITDA expansion.
• Attractive Valuation: Trading at less than 2x forward sales with a 32% discount to intrinsic value, the stock offers an asymmetric risk-to-reward ratio.

The Bear Case

• Margin Compression Persists: If the transition to lower-margin branded GLP-1 medications drags on, the company's long-term gross margin profile may permanently settle in the mid-60s, limiting GAAP net income potential.
• Fierce Competition: The telehealth space is becoming crowded. Competitors like Amazon One Medical, Teladoc, and Eli Lilly's direct-to-consumer platform (LillyDirect) are actively competing for the same pool of weight loss and wellness subscribers.
• Integration Risks: Merging a $1.15 billion international company like Eucalyptus carries significant execution risks, including cultural alignment, regulatory differences in Japan and Europe, and technological integration hurdles.

Frequently Asked Questions (FAQ) About HIMS Stock

Why did HIMS stock drop so heavily after its Q1 2026 earnings?

HIMS stock plunged roughly 23% post-earnings because the company reported an unexpected quarterly net loss of $92.1 million (against expectations of a profit) and experienced gross margin contraction from 73% to 65%. This was driven by $33 million in one-time restructuring costs and inventory write-downs as the company pivoted away from compounded GLP-1 copycats toward branded, FDA-approved medications.

Does Hims & Hers still sell compounded weight loss medications?

As part of its strategic collaboration with Novo Nordisk announced in March 2026, Hims & Hers has phased out the advertising and active promotion of compounded GLP-1 medications. The platform is actively transitioning its existing compounded semaglutide customers onto branded, FDA-approved alternatives like Wegovy. Compounded options will only be offered on a highly limited, clinically necessary basis.

Is the partnership with Novo Nordisk good for HIMS stock?

Yes, in the long term. While branded medications carry lower profit margins than compounded alternatives, the partnership completely eliminates the threat of patent litigation from Novo Nordisk and reduces regulatory risk from the FDA. It establishes Hims & Hers as a legitimate, trusted medical gateway, unlocking millions of potential patients who prefer branded, clinically-proven treatments.

What are the details of the Eucalyptus acquisition?

Hims & Hers agreed to acquire Eucalyptus Health, an international digital healthcare leader, for up to $1.15 billion. The deal includes $240 million in upfront cash, with the remainder tied to deferred payments and performance targets through 2029. Eucalyptus brings 775,000 active subscribers across Australia, the UK, Germany, Canada, and Japan, adding $450 million in annualized run-rate revenue.

Is HIMS stock a buy at current levels?

For investors with a medium-to-long-term horizon, HIMS stock appears highly attractive. Trading near its 200-day SMA at a forward EV/Sales multiple of 1.7x and boasting a 32% margin of safety to its intrinsic fair value, the current price represents a classic "buy the blood" opportunity as the company transitions into a highly scalable, globally diversified consumer health giant.

Conclusion

Wall Street's negative reaction to Hims & Hers Health's Q1 2026 earnings is a classic case of short-term market myopia. By looking past the temporary bottom-line net loss and margin contraction, it is easy to see that Hims & Hers is fundamentally transforming its business for the better.

The historic alliance with Novo Nordisk removes a catastrophic legal overhang and solidifies HIMS as a premier distributor of blockbuster weight loss drugs, while the $1.15 billion Eucalyptus acquisition establishes an immediate global footprint with massive scale. Supported by a raised full-year 2026 revenue guidance of $2.8B to $3.0B, a pristine cash position, and a 30%+ short interest poised for a squeeze, the current dip in hims stock is not a sign of a broken story—it is a prime accumulation window for patient, forward-looking investors.